NACA is a gene-agnostic, oral medication designed to preserve vision in people with retinitis pigmentosa and Usher syndrome.
--------
3:37
--------
3:37
Eye on the Cure Podcast | Episode 91: Dr. George Magrath
September 5, 2025. Dr. George Magrath, CEO of Opus Genetics, talks with host Ben Shaberman about the company's evolution and progress in clinically developing gene therapies for several inherited retinal diseases including those caused by mutations in the genes: LCA5, BEST1, RHO, RDH12, MERTK, NMNAT1, and CNGB1.
--------
22:19
--------
22:19
Opus Genetics Receives FDA Clearance to Launch Clinical Trial for Best1 Gene Therapy
The Foundation funded earlier, proof-of-concept studies for the Best1 gene therapy and later launched Opus to develop several IRD gene therapies.
--------
2:07
--------
2:07
jCyte Launches New Phase 2 Clinical Trial for its Cell-Based RP Therapy
The trial is evaluating a cell dose that is 50 percent higher than the highest dose used in a previous Phase 2b trial.
--------
3:07
--------
3:07
Eye on the Cure Podcast | Episode 90: Dr. Christina Ohnsman
August 8, 2025. Dr. Christina Ohnsman talks to host Ben Shaberman about Tern Therapeutics, a start-up company she co-founded to develop gene therapies for Batten disease and potentially other conditions. Dr. Ohnsman reviews early results for a Batten disease (CLN2) retinal gene therapy clinical trial. She also reflects on her previous work as a pediatric ophthalmologist and roles with Spark Therapeutics and Regenxbio.
The Foundation Fighting Blindness is the driving force in the global development of treatments and cures for blinding diseases. To learn more, go to FightingBlindness.org.
Netherlands